BioMarin Pharmaceutical | BMRN - Debt

Biomarin Pharmaceutical reported $1.09B in Debt for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Debt Change
Acorda Therapeutics ACOR:US USD 167.03M 20.66M
Alnylam Pharmaceuticals ALNY:US USD 1.02B 967K
Amgen AMGN:US USD 38.94B 241M
Bayer BAYN:GR EUR 41.65B 3.14B
Biogen BIIB:US USD 6.28B 1.8M
Biomarin Pharmaceutical BMRN:US USD 1.09B 3.46M
Insmed INSM:US USD 1.16B 348.29M
Intercept Pharmaceuticals ICPT:US USD 332.67M 365K
IONIS PHARMACEUT IONS:US USD 1.19B 64.22M
Moderna Inc MRNA:US USD 1.07B 73M
Neurocrine Biosciences NBIX:US USD 169.4M 200K
Ptc Therapeutics PTCT:US USD 1.35B 289.13M
Puma Biotechnology PBYI:US USD 98.31M 313K
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Roche Holding ROG:VX 25.35B 2.4B
Sarepta Therapeutics SRPT:US USD 1.54B 1.52M
United Therapeutics UTHR:US USD 800M 0
Vertex Pharmaceuticals VRTX:US USD 471.6M 29.3M
YTE INCY:US USD 33.26M 326K